Research Desk Line-up: Advaxis Post Earnings Coverage
LONDON, UK / ACCESSWIRE / September 18, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Tesaro, Inc. (NASDAQ: TSRO), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=TSRO. The Company announced on September 15, 2017, that the European Medicines Agency`s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended a positive view for marketing authorization application for ZEJULA® (niraparib), as a monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete response (CR) or partial response (PR) to platinum-based chemotherapy. For immediate access to our complimentary reports, including today's coverage, register for free now at:
Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Advaxis, Inc. (NASDAQ: ADXS) for due-diligence and potential coverage as the Company provided on September 11, 2017, a business update and also announced its financial results for Q3 2017 which ended on July 31, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Advaxis when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on TSRO; also brushing on ADXS. Go directly to your stock of interest and access today’s free coverage at:
The recommendation will be referred to the European Commission (EC), for receiving marketing authorization of ZEJULA in the European Union. Once approved by the EC, ZEJULA would be the first oral, once-daily poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor approved in Europe for use in patients regardless of BRCA mutation or biomarker status.
ZEJULA's NOVA Trial, Phase-3 Study
- The marketing authorization application is supported by data from the ENGOT-OV16/NOVA trial, an international Phase-3 study of ZEJULA.
- The study enrolled 553 patients with recurrent ovarian cancer who had achieved either a PR or CR to their most recent platinum-based chemotherapy. Two-thirds of study participants did not have germline BRCA mutations.
- Results indicated that ZEJULA significantly increased progression-free survival (PFS) in patients with and without germline BRCA mutations compared to the control arm.
- It was also found that treatment with ZEJULA reduced the risk of the disease progression or death by 73% in patients with germline BRCA mutations and by 55% in patients without germline BRCA mutations, with similar magnitude of benefit for patients entering the trial with a PR or a CR.
- The most common adverse reactions to ZEJULA included thrombocytopenia, anemia, neutropenia, and hypertension. The majority of hematologic adverse events were successfully managed via dose modification.
Phase-3 NOVA Trial Generated Unsurpassed Efficacy Results in Patients with Recurrent Ovarian Cancer
Mary Lynne Hedley, Ph.D., President and COO of TESARO, stated that ZEJULA was studied with the highest level of clinical rigor, and the Phase-3 NOVA trial generated unsurpassed efficacy results in patients with recurrent ovarian cancer, including women without germline BRCA mutations who have the most challenging prognosis and few treatment options. She added that the positive CHMP opinion brings TESARO one step closer to providing important new medicine to patients with recurrent ovarian cancer in Europe.
TESARO to Launch ZEJULA across Multiple Countries in Europe
Orlando Oliveira, Senior Vice President and General Manager of TESARO International, stated that the Company is rapidly globalizing its mission of providing transformative oncology therapies to those who need them most. Upon final approval by the EC, the Company intends to launch ZEJULA across multiple countries in Europe where it already has an established, direct presence, beginning in the fourth quarter.
ZEJULA Received FDA Approval in March 2017
News release suggests that on March 27, 2017, TESARO received approval from FDA for ZEJULA, becoming the first PARP inhibitor to be approved by the FDA that did not require BRCA mutation or another biomarker testing. On April 19, 2017, TESARO announced the availability of ZEJULA by prescription in the United States.
ZEJULA (niraparib) is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Ovarian Cancer in Europe
Europe has one of the highest incidences of ovarian cancer in the world with around 45,000 women diagnosed there every year. Ovarian cancer affects approximately 1.3 in 10,000 people in the European Union. Despite high initial response rates to platinum-based chemotherapy, approximately 85% of women with advanced ovarian cancer will experience a recurrence of the disease after first-line treatment.
About Tesaro Inc.
Founded in 2010, TESARO is a biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. The Company is headquartered in Waltham, Massachusetts.
Last Close Stock Review
On Friday, September 15, 2017, the stock closed the trading session at $117.16, advancing 1.67% from its previous closing price of $115.24. A total volume of 1.25 million shares have exchanged hands, which was higher than the 3-month average volume of 1.17 million shares. Tesaro's stock price rallied 3.69% in the last one month and 18.60% in the previous twelve months. The stock currently has a market cap of $6.24 billion.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily